TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE) today announced that Dr. Michael Bumby has resigned as CFO, effective August 1, 2015. Antibe wishes to thank Dr. Bumby for his efforts in taking the Company public in 2013. Samira Sakhia has been named the Company’s CFO on an interim basis replacing Dr. Bumby. Ms. Sakhia, currently a member of Antibe’s board of directors, brings a wealth of experience to the CFO role. She was the CFO of Paladin Labs Inc. f